Clinical outcomes after allogeneic HCT with nonmyeloablative conditioning
. | . | Invasive mold infection . | . | |
|---|---|---|---|---|
. | Total . | Yes . | No . | |
| Acute GVHD grades II-IV, n (%) | ||||
| Yes | 99 | 21 (21) | 78 (79) | |
| No | 64 | 4 (6) | 60 (94) | |
| Acute GVHD grades III-IV, n (%) | ||||
| Yes | 25 | 10 (40) | 15 (60) | |
| No | 138 | 15 (11) | 123 (89) | |
| Chronic extensive GVHD, n (%) | ||||
| Yes | 82 | 15 (18) | 67 (82) | |
| No | 60 | 5 (8) | 55 (92) | |
| Corticosteroids for GVHD, n (%) | ||||
| None | 41 | 1 (2) | 40 (98) | |
| 1 mg/kg | 55 | 7 (13) | 48 (87) | |
| 2 mg/kg | 67 | 17 (25) | 50 (75) | |
| CMV antigenemia, n (%) | ||||
| Yes | 64 | 14 (22) | 50 (78) | |
| No | 99 | 11 (11) | 88 (89) | |
| CMV disease, n (%) | ||||
| Yes | 14 | 9 (64) | 5 (36) | |
| No | 149 | 16 (11) | 133 (89) | |
| Nonrelapse mortality, n (%) | ||||
| Yes | 36 | 16 (44) | 20 (56) | |
| No | 127 | 9 (7) | 118 (93) | |
. | . | Invasive mold infection . | . | |
|---|---|---|---|---|
. | Total . | Yes . | No . | |
| Acute GVHD grades II-IV, n (%) | ||||
| Yes | 99 | 21 (21) | 78 (79) | |
| No | 64 | 4 (6) | 60 (94) | |
| Acute GVHD grades III-IV, n (%) | ||||
| Yes | 25 | 10 (40) | 15 (60) | |
| No | 138 | 15 (11) | 123 (89) | |
| Chronic extensive GVHD, n (%) | ||||
| Yes | 82 | 15 (18) | 67 (82) | |
| No | 60 | 5 (8) | 55 (92) | |
| Corticosteroids for GVHD, n (%) | ||||
| None | 41 | 1 (2) | 40 (98) | |
| 1 mg/kg | 55 | 7 (13) | 48 (87) | |
| 2 mg/kg | 67 | 17 (25) | 50 (75) | |
| CMV antigenemia, n (%) | ||||
| Yes | 64 | 14 (22) | 50 (78) | |
| No | 99 | 11 (11) | 88 (89) | |
| CMV disease, n (%) | ||||
| Yes | 14 | 9 (64) | 5 (36) | |
| No | 149 | 16 (11) | 133 (89) | |
| Nonrelapse mortality, n (%) | ||||
| Yes | 36 | 16 (44) | 20 (56) | |
| No | 127 | 9 (7) | 118 (93) | |
N = 163; with invasive mold infection: n = 25 patients (15%); without invasive mold infection: n = 138 patients (85%)